Bank of America’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-647,487
| Closed | -$83M | – | 8320 |
|
|
2025
Q2 | $83M | Sell |
647,487
-69,419
| -10% | -$7.21M | 0.01% | 1292 |
|
|
2025
Q1 | $63.5M | Buy |
716,906
+321,875
| +81% | +$31.4M | 0.01% | 1391 |
|
|
2024
Q4 | $34.5M | Sell |
395,031
-16,424
| -4% | -$1.5M | ﹤0.01% | 1808 |
|
|
2024
Q3 | $38.1M | Buy |
411,455
+7,759
| +2% | +$771K | ﹤0.01% | 1800 |
|
|
2024
Q2 | $43.5M | Buy |
403,696
+67,921
| +20% | +$6.8M | ﹤0.01% | 1556 |
|
|
2024
Q1 | $31.9M | Buy |
335,775
+24,559
| +8% | +$2.11M | ﹤0.01% | 1850 |
|
|
2023
Q4 | $28.7M | Sell |
311,216
-85,207
| -21% | -$5.52M | ﹤0.01% | 1814 |
|
|
2023
Q3 | $19.9M | Buy |
396,423
+68,321
| +21% | +$3.65M | ﹤0.01% | 2035 |
|
|
2023
Q2 | $20.7M | Sell |
328,102
-84,921
| -21% | -$4.62M | ﹤0.01% | 2005 |
|
|
2023
Q1 | $18.6M | Buy |
413,023
+76,942
| +23% | +$3.47M | ﹤0.01% | 2194 |
|
|
2022
Q4 | $14.7M | Buy |
336,081
+58,227
| +21% | +$2.79M | ﹤0.01% | 2297 |
|
|
2022
Q3 | $18.3M | Sell |
277,854
-73,240
| -21% | -$4.7M | ﹤0.01% | 2046 |
|
|
2022
Q2 | $17.7M | Sell |
351,094
-15,997
| -4% | -$937K | ﹤0.01% | 2119 |
|
|
2022
Q1 | $23.4M | Buy |
367,091
+81,501
| +29% | +$5.85M | ﹤0.01% | 1998 |
|
|
2021
Q4 | $30.6M | Buy |
285,590
+24,448
| +9% | +$2.56M | ﹤0.01% | 1810 |
|
|
2021
Q3 | $26.8M | Buy |
261,142
+2,585
| +1% | +$241K | ﹤0.01% | 1904 |
|
|
2021
Q2 | $22.7M | Buy |
258,557
+17,278
| +7% | +$1.58M | ﹤0.01% | 2022 |
|
|
2021
Q1 | $23.5M | Buy |
241,279
+44,536
| +23% | +$4.45M | ﹤0.01% | 1903 |
|
|
2020
Q4 | $22.1M | Sell |
196,743
-38,140
| -16% | -$4.02M | ﹤0.01% | 1788 |
|
|
2020
Q3 | $21.8M | Buy |
234,883
+84,012
| +56% | +$6.47M | ﹤0.01% | 1635 |
|
|
2020
Q2 | $11.8M | Buy |
150,871
+62,675
| +71% | +$4.24M | ﹤0.01% | 2061 |
|
|
2020
Q1 | $5.16M | Buy |
88,196
+11,241
| +15% | +$723K | ﹤0.01% | 2638 |
|
|
2019
Q4 | $6.17M | Sell |
76,955
-23,524
| -23% | -$1.76M | ﹤0.01% | 3042 |
|
|
2019
Q3 | $7.38M | Sell |
100,479
-12,534
| -11% | -$1.08M | ﹤0.01% | 2821 |
|
|
2019
Q2 | $10.7M | Buy |
113,013
+6,739
| +6% | +$556K | ﹤0.01% | 2493 |
|
|
2019
Q1 | $8.51M | Buy |
106,274
+36,601
| +53% | +$2.7M | ﹤0.01% | 2653 |
|
|
2018
Q4 | $3.76M | Sell |
69,673
-29,361
| -30% | -$1.78M | ﹤0.01% | 3284 |
|
|
2018
Q3 | $7.73M | Sell |
99,034
-3,187
| -3% | -$222K | ﹤0.01% | 2751 |
|
|
2018
Q2 | $6.49M | Buy |
102,221
+72,250
| +241% | +$5.75M | ﹤0.01% | 2881 |
|
|
2018
Q1 | $2.75M | Buy |
29,971
+16,579
| +124% | +$1.43M | ﹤0.01% | 3627 |
|
|
2017
Q4 | $1.01M | Buy |
13,392
+468
| +4% | +$32.9K | ﹤0.01% | 4481 |
|
|
2017
Q3 | $900K | Buy |
12,924
+7,185
| +125% | +$384K | ﹤0.01% | 4582 |
|
|
2017
Q2 | $291K | Sell |
5,739
-2,351
| -29% | -$99.8K | ﹤0.01% | 5147 |
|
|
2017
Q1 | $324K | Buy |
8,090
+4,144
| +105% | +$148K | ﹤0.01% | 5100 |
|
|
2016
Q4 | $110K | Buy |
3,946
+2,721
| +222% | +$82K | ﹤0.01% | 5579 |
|
|
2016
Q3 | $36K | Sell |
1,225
-1,106
| -47% | -$27.5K | ﹤0.01% | 5860 |
|
|
2016
Q2 | $47K | Buy |
2,331
+1,453
| +165% | +$26.4K | ﹤0.01% | 5852 |
|
|
2016
Q1 | $16K | Sell |
878
-11,827
| -93% | -$205K | ﹤0.01% | 6221 |
|
|
2015
Q4 | $335K | Buy |
12,705
+5,421
| +74% | +$122K | ﹤0.01% | 5064 |
|
|
2015
Q3 | $155K | Buy |
7,284
+7,025
| +2,712% | +$194K | ﹤0.01% | 5464 |
|
|
2015
Q2 | $7K | Buy |
+259
| New | +$7.4K | ﹤0.01% | 6701 |
|
Other funds holding BPMC
IA
HNB
Bank of America's BPMC Position: Q3 2025 in Review
Bank of America sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 647,487 shares — an estimated $83M sold.
Bank of America first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $83M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Bank of America reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Bank of America sold 647,487 Blueprint Medicines shares in Q3 2025, an estimated $83M.
- Bank of America first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
- Bank of America's Blueprint Medicines position peaked at $83M in Q2 2025.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Bank of America's 13F filing for Q3 2025, filed 14 Nov 2025.